BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Growth in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 3,600 shares, an increase of 125.0% from the February 13th total of 1,600 shares. Based on an average daily volume of 90,200 shares, the short-interest ratio is presently 0.0 days.

BriaCell Therapeutics Stock Performance

BriaCell Therapeutics stock opened at $0.09 on Friday. The firm’s fifty day moving average price is $0.13 and its 200-day moving average price is $0.25. BriaCell Therapeutics has a fifty-two week low of $0.07 and a fifty-two week high of $1.70.

About BriaCell Therapeutics

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

See Also

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.